Health Care White Crystalline Effictive Tetracaine Pharmaceutical Raw Materials
Abstrait
| Nom |
Tétracaïne |
| Chemical name |
2-(Dimethylamino)éthyle 4-(butylamino)benzoate; 2-
(Dimethylamino)ethyl p-(butylamino)benzoate; |
| Synonyme |
4-(butylamino)-benzoicaci2-(dimethylamino) ethylester
; Amethocaine; Anetain |
| n ° CAS |
94-24-6 |
| Formule moléculaire |
C15H24N2O2 |
| Masse moléculaire |
264.36 |
| Pureté |
99% |
| Apparence |
Poudre cristalline blanche |
| Attestation |
USP/ISO9001 |
| Standard |
Norme d'entreprise |
La description
Tetracaine was patented in 1930 and came into medical use in 1941.
It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 1.34 à 1.63 USD per 10 ml bottle.
Application
1. In biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. Tetracaine is an allosteric blocker of channel function. At low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely.
2. Tetracaine is the T in Tac, a mixture of 5 à 12 per cent tetracaine, 5M(per myriad), a half per mille (0.5‰), ou .05 per cent (1 part in 2000) , et 4 ou 10 per cent hydrochloride used in ear, nose & throat surgery and in the emergemcy department where numbing of the surface is needed rapidly, especially when children have been injured in the eye, ear, or other sensitive locations.
3. Tetracaine is synthesized from 4-butylaminobenzoic acid. The ethyl ester is formed through an acid-catalyzed esterification reaction. Base-catalyzed transesterification is achieved by boiling the ethyl ester of 4-butylaminobenzoic acid with excess 2-dimethylaminoethanol in the presence of a small amount of sodium ethoxide.
Directeur commercial